GTBP

GT Biopharma Inc

NASDAQ: GTBP · HEALTHCARE · BIOTECHNOLOGY

$0.31

+5.70% today

Updated 2026-06-02

Market cap

$15.74M

P/E ratio

—

P/S ratio

204.96x

EPS (TTM)

$-6.46

Dividend yield

—

52W range

$0 – $4

Volume

1.3M

Market cap

$15.74M

P/E ratio

—

P/S ratio

204.96x

EPS (TTM)

$-6.46

Dividend yield

—

52W range

$0 – $4

Volume

1.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.3

Valuation

C+

2/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$3.00

+859.39%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-2.47M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-20.88M	$-7.60M	$-13.16M	$-28.35M	$-2.83M
EPS	—	—	—	—	$-6.46
Free cash flow	$-15.22M	$-8.85M	$-12.90M	$-12.91M	$-2.47M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
GTBP	$15.74M	29	4.3	3.0	5.3	6.0	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

GT Biopharma Inc trades at $0.31. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score.

Frequently asked questions

What is GT Biopharma Inc's stock price?

GT Biopharma Inc (GTBP) trades at $0.31, on a P/S of 205.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.

Is GT Biopharma Inc overvalued?

GT Biopharma Inc carries a Smart Value Score of 29/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of GT Biopharma Inc (GTBP)?

The 12-month analyst consensus target is $3.00, about 859.4% above the current $0.31. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio204.96x

ROE-629.74%

Beta0.86

50D MA$0.39

200D MA$0.62

Shares out0.04B

Float0.03B

Short ratio—

Avg volume1.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

GTBP vs LLY →GTBP vs JNJ →GTBP vs ABBV →Stock screener →